
Pfizer shows strong new drug growth and backs a 6% dividend despite patent challenges.
Pfizer is navigating typical pharmaceutical challenges like patent expirations on key drugs but is offsetting revenue losses with a 32% rise in sales from new and acquired products. The company maintains a strong financial position with $1.8 billion ...





